

# Pablo M Rusjan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7216927/publications.pdf>

Version: 2024-02-01

126  
papers

8,466  
citations

34105

52  
h-index

48315

88  
g-index

134  
all docs

134  
docs citations

134  
times ranked

8825  
citing authors

#	ARTICLE	IF	CITATIONS
1	In vivo imaging translocator protein (TSPO) in autism spectrum disorder. <i>Neuropsychopharmacology</i> , 2022, 47, 1421-1427.	5.4	10
2	Investigating the use of plasma pTau181 in retired contact sports athletes. <i>Journal of Neurology</i> , 2022, 269, 5582-5595.	3.6	4
3	Microglia imaging in methamphetamine use disorder: a positron emission tomography study with the 18 kDa translocator protein radioligand [ <sup>18</sup> F]FEPPA. <i>Addiction Biology</i> , 2021, 26, e12876.	2.6	10
4	Fatty acid amide hydrolase is lower in young cannabis users. <i>Addiction Biology</i> , 2021, 26, e12872.	2.6	21
5	Meta-analysis of the Glial Marker TSPO in Psychosis Revisited: Reconciling Inconclusive Findings of Patientâ€Control Differences. <i>Biological Psychiatry</i> , 2021, 89, e5-e8.	1.3	36
6	Lower amygdala fatty acid amide hydrolase in violent offenders with antisocial personality disorder: an [ <sup>11</sup> C]CURB positron emission tomography study. <i>Translational Psychiatry</i> , 2021, 11, 57.	4.8	13
7	A double-blind placebo-controlled trial of minocycline on translocator protein distribution volume in treatment-resistant major depressive disorder. <i>Translational Psychiatry</i> , 2021, 11, 334.	4.8	9
8	Genetically Predicted Brain C4A Expression Is Associated With TSPO and Hippocampal Morphology. <i>Biological Psychiatry</i> , 2021, 90, 652-660.	1.3	12
9	Concentration, distribution, and influence of aging on the 18 kDa translocator protein in human brain: Implications for brain imaging studies. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 1061-1076.	4.3	13
10	Stress-induced cortical dopamine response is altered in subjects at clinical high risk for psychosis using cannabis. <i>Addiction Biology</i> , 2020, 25, e12812.	2.6	9
11	The Interaction Between Neuroinflammation and $\beta$ -Amyloid in Cognitive Decline in Parkinson's Disease. <i>Molecular Neurobiology</i> , 2020, 57, 492-501.	4.0	23
12	Replicating predictive serum correlates of greater translocator protein distribution volume in brain. <i>Neuropsychopharmacology</i> , 2020, 45, 925-931.	5.4	20
13	Translocator Protein Distribution Volume Predicts Reduction of Symptoms During Open-Label Trial of Celecoxib in Major Depressive Disorder. <i>Biological Psychiatry</i> , 2020, 88, 649-656.	1.3	32
14	Elevated fatty acid amide hydrolase in the prefrontal cortex of borderline personality disorder: a [ <sup>11</sup> C]CURB positron emission tomography study. <i>Neuropsychopharmacology</i> , 2020, 45, 1834-1841.	5.4	23
15	Imaging Brain Fatty Acid Amide Hydrolase in Untreated Patients With Psychosis. <i>Biological Psychiatry</i> , 2020, 88, 727-735.	1.3	18
16	PET Tau Imaging and Motor Impairments Differ Between Corticobasal Syndrome and Progressive Supranuclear Palsy With and Without Alzheimer's Disease Biomarkers. <i>Frontiers in Neurology</i> , 2020, 11, 574.	2.4	7
17	Interaction of APOE4 alleles and PET tau imaging in former contact sport athletes. <i>NeuroImage: Clinical</i> , 2020, 26, 102212.	2.7	15
18	Lower brain fatty acid amide hydrolase in treatment-seeking patients with alcohol use disorder: a positron emission tomography study with [ <sup>11</sup> C]CURB. <i>Neuropsychopharmacology</i> , 2020, 45, 1289-1296.	5.4	28

#	ARTICLE	IF	CITATIONS
19	On the relationship of first-episode psychosis to the amphetamine-sensitized state: a dopamine D2/3 receptor agonist radioligand study. <i>Translational Psychiatry</i> , 2020, 10, 2.	4.8	25
20	Exploring occupancy of the histamine H <sub>3</sub> receptor by pitolisant in humans using PET. <i>British Journal of Pharmacology</i> , 2020, 177, 3464-3472.	5.4	15
21	Personality traits in psychosis and psychosis risk linked to TSPO expression: a neuroimmune marker. <i>Personality Neuroscience</i> , 2020, 3, e14.	1.6	1
22	Impaired Prefrontal Cortical Dopamine Release in Schizophrenia During a Cognitive Task: A [11C]FLB 457 Positron Emission Tomography Study. <i>Schizophrenia Bulletin</i> , 2019, 45, 670-679.	4.3	39
23	Prefrontal cortical dopamine release in clinical high risk for psychosis during a cognitive task: a [11C]FLB457 positron emission tomography study. <i>European Neuropsychopharmacology</i> , 2019, 29, 1023-1032.	0.7	2
24	In Vivo Imaging of Translocator Protein in Long-term Cannabis Users. <i>JAMA Psychiatry</i> , 2019, 76, 1305.	11.0	34
25	Monoamine Oxidase B Total Distribution Volume in the Prefrontal Cortex of Major Depressive Disorder. <i>JAMA Psychiatry</i> , 2019, 76, 634.	11.0	74
26	DRD2 Genotype-Based Variants Modulates D2 Receptor Distribution in Ventral Striatum. <i>Molecular Neurobiology</i> , 2019, 56, 6512-6520.	4.0	6
27	Preliminary data indicating a connection between stress-induced prefrontal dopamine release and hippocampal TSPO expression in the psychosis spectrum. <i>Schizophrenia Research</i> , 2019, 213, 80-86.	2.0	8
28	GABA levels and TSPO expression in people at clinical high risk for psychosis and healthy volunteers: a PET-MRS study. <i>Journal of Psychiatry and Neuroscience</i> , 2019, 44, 111-119.	2.4	26
29	Positron Emission Tomography Studies of the Glial Cell Marker Translocator Protein in Patients With Psychosis: A Meta-analysis Using Individual Participant Data. <i>Biological Psychiatry</i> , 2018, 84, 433-442.	1.3	103
30	Association of translocator protein total distribution volume with duration of untreated major depressive disorder: a cross-sectional study. <i>Lancet Psychiatry</i> , 2018, 5, 339-347.	7.4	192
31	Interaction between TSPO—a neuroimmune marker—and redox status in clinical high risk for psychosis: a PET-MRS study. <i>Neuropsychopharmacology</i> , 2018, 43, 1700-1705.	5.4	22
32	Nigral Stress-Induced Dopamine Release in Clinical High Risk and Antipsychotic-Naïve Schizophrenia. <i>Schizophrenia Bulletin</i> , 2018, 44, 542-551.	4.3	26
33	[18F]AV-1451 binding to neuromelanin in the substantia nigra in PD and PSP. <i>Brain Structure and Function</i> , 2018, 223, 589-595.	2.3	36
34	Imaging microglial activation and amyloid burden in amnesic mild cognitive impairment. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2018, 38, 1885-1895.	4.3	29
35	Cortical stress regulation is disrupted in schizophrenia but not in clinical high risk for psychosis. <i>Brain</i> , 2018, 141, 2213-2224.	7.6	32
36	TSPO expression and brain structure in the psychosis spectrum. <i>Brain, Behavior, and Immunity</i> , 2018, 74, 79-85.	4.1	17

#	ARTICLE	IF	CITATIONS
37	Voxel level quantification of [ <sup>11</sup> C]CURB, a radioligand for Fatty Acid Amide Hydrolase, using high resolution positron emission tomography. PLoS ONE, 2018, 13, e0192410.	2.5	3
38	Microglial activation in Parkinson's disease using [ <sup>18</sup> F]-FEPPA. Journal of Neuroinflammation, 2017, 14, 8.	7.2	88
39	The Relationship Between Serotonin 2A Receptor and Cognitive Functions in Nondemented Parkinson's Disease Patients with Visual Hallucinations. Movement Disorders Clinical Practice, 2017, 4, 698-709.	1.5	23
40	Positron emission tomography imaging of tau pathology in progressive supranuclear palsy. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 3150-3160.	4.3	48
41	Inflammation in the Neurocircuitry of Obsessive-Compulsive Disorder. JAMA Psychiatry, 2017, 74, 833.	11.0	132
42	Imaging Microglial Activation in Individuals at Clinical High Risk for Psychosis: an In Vivo PET Study with [ <sup>18</sup> F]FEPPA. Neuropsychopharmacology, 2017, 42, 2474-2481.	5.4	47
43	Neuroimaging and clinical features in adults with a 22q11.2 deletion at risk of Parkinson's disease. Brain, 2017, 140, 1371-1383.	7.6	41
44	Imaging Microglial Activation in Untreated First-Episode Psychosis: A PET Study With [ <sup>18</sup> F]FEPPA. American Journal of Psychiatry, 2017, 174, 118-124.	7.2	103
45	Inhibition of fatty acid amide hydrolase by BIA 10-2474 in rat brain. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 3635-3639.	4.3	10
46	Elevated Striatal Dopamine Function in Immigrants and Their Children: A Risk Mechanism for Psychosis. Schizophrenia Bulletin, 2017, 43, sbw181.	4.3	44
47	Feasibility study of TSPO quantification with [ <sup>18</sup> F]FEPPA using population-based input function. PLoS ONE, 2017, 12, e0177785.	2.5	20
48	Fatty Acid Amide Hydrolase Binding in Brain of Cannabis Users: Imaging With the Novel Radiotracer [ <sup>11</sup> C]CURB. Biological Psychiatry, 2016, 80, 691-701.	1.3	53
49	Serotonin transporter binding is reduced in seasonal affective disorder following light therapy. Acta Psychiatrica Scandinavica, 2016, 134, 410-419.	4.5	30
50	Heightened Dopaminergic Response to Amphetamine at the D3 Dopamine Receptor in Methamphetamine Users. Neuropsychopharmacology, 2016, 41, 2994-3002.	5.4	62
51	D <sub>3</sub> dopamine receptor-preferring [ <sup>11</sup> C]PHNO PET imaging in Parkinson patients with dyskinesia. Neurology, 2016, 86, 224-230.	1.1	49
52	Monoamine Oxidase-A Occupancy by Moclobemide and Phenzelzine: Implications for the Development of Monoamine Oxidase Inhibitors. International Journal of Neuropsychopharmacology, 2016, 19, pyv078.	2.1	27
53	Light therapy and serotonin transporter binding in the anterior cingulate and prefrontal cortex. Acta Psychiatrica Scandinavica, 2015, 132, 379-388.	4.5	24
54	Similar striatal D2/D3 dopamine receptor availability in adults with Tourette syndrome compared with healthy controls: A [ <sup>11</sup> C]PHNO and [ <sup>11</sup> C]raclopride positron emission tomography imaging study. Human Brain Mapping, 2015, 36, 2592-2601.	3.6	17

#	ARTICLE	IF	CITATIONS
55	Imaging Striatal Microglial Activation in Patients with Parkinson's Disease. PLoS ONE, 2015, 10, e0138721.	2.5	95
56	Imaging Neuroinflammation in Gray and White Matter in Schizophrenia: An In-Vivo PET Study With [18F]-FEPPA. Schizophrenia Bulletin, 2015, 41, 85-93.	4.3	158
57	[ <sup>11</sup> C]-(+)-PHNO PET imaging of dopamine D <sub>2/3</sub> receptors in Parkinson's disease with impulse control disorders. Movement Disorders, 2015, 30, 160-166.	3.9	65
58	Relationship of Monoamine Oxidase-A Distribution Volume to Postpartum Depression and Postpartum Crying. Neuropsychopharmacology, 2015, 40, 429-435.	5.4	67
59	The Fatty Acid Amide Hydrolase C385A Variant Affects Brain Binding of the Positron Emission Tomography Tracer [ <sup>11</sup> C]CURB. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 1237-1240.	4.3	58
60	Blocking of Fatty Acid Amide Hydrolase Activity with PF-04457845 in Human Brain: A Positron Emission Tomography Study with the Novel Radioligand [ <sup>11</sup> C]CURB. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 1827-1835.	4.3	28
61	In-vivo imaging of grey and white matter neuroinflammation in Alzheimer's disease: a positron emission tomography study with a novel radioligand, [18F]-FEPPA. Molecular Psychiatry, 2015, 20, 1579-1587.	7.9	101
62	Role of Translocator Protein Density, a Marker of Neuroinflammation, in the Brain During Major Depressive Episodes. JAMA Psychiatry, 2015, 72, 268.	11.0	700
63	Saliency network and parahippocampal dopamine dysfunction in memory-impaired Parkinson disease. Annals of Neurology, 2015, 77, 269-280.	5.3	93
64	Investing in the Future: Stimulation of the Medial Prefrontal Cortex Reduces Discounting of Delayed Rewards. Neuropsychopharmacology, 2015, 40, 546-553.	5.4	89
65	Elevated Monoamine Oxidase A Binding During Major Depressive Episodes Is Associated with Greater Severity and Reversed Neurovegetative Symptoms. Neuropsychopharmacology, 2014, 39, 973-980.	5.4	53
66	Kinetic Modeling of the Monoamine Oxidase B Radioligand [ <sup>11</sup> C]SL25.1188 in Human Brain with High-Resolution Positron Emission Tomography. Journal of Cerebral Blood Flow and Metabolism, 2014, 34, 883-889.	4.3	83
67	Heightened D3 Dopamine Receptor Levels in Cocaine Dependence and Contributions to the Addiction Behavioral Phenotype: A Positron Emission Tomography Study with [11C]-(+)-PHNO. Neuropsychopharmacology, 2014, 39, 311-318.	5.4	99
68	Quantitative imaging of neuroinflammation in human white matter: A positron emission tomography study with translocator protein 18 kDa radioligand, [ <sup>18</sup> F]-FEPPA. Synapse, 2014, 68, 536-547.	1.2	17
69	Greater Monoamine Oxidase A Binding in Perimenopausal Age as Measured With Carbon 11-Labeled Harmine Positron Emission Tomography. JAMA Psychiatry, 2014, 71, 873.	11.0	58
70	Whole-Body Radiation Dosimetry of <sup>11</sup> C-Carbonyl-URB694: A PET Tracer for Fatty Acid Amide Hydrolase. Journal of Nuclear Medicine, 2014, 55, 1993-1997.	5.0	15
71	Combined insular and striatal dopamine dysfunction are associated with executive deficits in Parkinson's disease with mild cognitive impairment. Brain, 2014, 137, 565-575.	7.6	116
72	Neuroinflammation in healthy aging: A PET study using a novel Translocator Protein 18kDa (TSPO) radioligand, [18F]-FEPPA. NeuroImage, 2014, 84, 868-875.	4.2	56

#	ARTICLE	IF	CITATIONS
73	Greater Monoamine Oxidase A Binding in Alcohol Dependence. <i>Biological Psychiatry</i> , 2014, 75, 756-764.	1.3	21
74	Elevation of Dopamine Induced by Cigarette Smoking: Novel Insights from a [ <sup>11</sup> C]-(+)-PHNO PET Study in Humans. <i>Neuropsychopharmacology</i> , 2014, 39, 415-424.	5.4	54
75	Stress-Induced Dopamine Response in Subjects at Clinical High Risk for Schizophrenia with and without Concurrent Cannabis Use. <i>Neuropsychopharmacology</i> , 2014, 39, 1479-1489.	5.4	86
76	Image Derived Input Function for [ <sup>18</sup> F]-FEPPA: Application to Quantify Translocator Protein (18 kDa) in the Human Brain. <i>PLoS ONE</i> , 2014, 9, e115768.	2.5	11
77	Prefrontal dopaminergic receptor abnormalities and executive functions in Parkinson's disease. <i>Human Brain Mapping</i> , 2013, 34, 1591-1604.	3.6	52
78	Whole Body Biodistribution and Radiation Dosimetry in Humans of a New PET Ligand, [ <sup>18</sup> F]-FEPPA, to Image Translocator Protein (18 kDa). <i>Molecular Imaging and Biology</i> , 2013, 15, 353-359.	2.6	23
79	Dopamine Response to Psychosocial Stress in Chronic Cannabis Users: A PET Study With [ <sup>11</sup> C]-(+)-PHNO. <i>Neuropsychopharmacology</i> , 2013, 38, 673-682.	5.4	45
80	The <sup>2/3</sup> dopamine receptor in pathological gambling: a positron emission tomography study with [ <sup>11</sup> C]-(+)-propylhexahydro-naphtho-oxazin and [ <sup>11</sup> C]-raclopride. <i>Addiction</i> , 2013, 108, 953-963.	3.3	167
81	Dopamine D2 and D3 binding in people at clinical high risk for schizophrenia, antipsychotic-naïve patients and healthy controls while performing a cognitive task. <i>Journal of Psychiatry and Neuroscience</i> , 2013, 38, 98-106.	2.4	36
82	Mapping Human Brain Fatty Acid Amide Hydrolase Activity with PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 407-414.	4.3	65
83	Voxel-Based Imaging of Translocator Protein 18Kda (TSPO) in High-Resolution PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 348-350.	4.3	10
84	Presentation of Smoking-Associated Cues Does Not Elicit Dopamine Release after One-Hour Smoking Abstinence: A [ <sup>11</sup> C]-(+)-PHNO PET Study. <i>PLoS ONE</i> , 2013, 8, e60382.	2.5	11
85	Translocator Protein (18 kDa) Polymorphism (rs6971) Explains <i>in-vivo</i> Brain Binding Affinity of the PET Radioligand [ <sup>18</sup> F]-FEPPA. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012, 32, 968-972.	4.3	131
86	Whole-Body Distribution and Radiation Dosimetry of <sup>11</sup> C-(+)-PHNO, a <sup>2/3</sup> Agonist Ligand. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1802-1806.	5.0	1
87	Convergent Effects of Acute Stress and Glucocorticoid Exposure upon MAO-A in Humans. <i>Journal of Neuroscience</i> , 2012, 32, 17120-17127.	3.6	29
88	Dynamic, Adaptive Changes in MAO-A Binding after Alterations in Substrate Availability: An <i>in vivo</i> [ <sup>11</sup> C]-Harmine Positron Emission Tomography Study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012, 32, 443-446.	4.3	27
89	Higher Binding of the Dopamine D <sub>3</sub> Receptor-Preferring Ligand [ <sup>11</sup> C]-(+)-Propyl-Hexahydro-Naphtho-Oxazin in Methamphetamine Polydrug Users: A Positron Emission Tomography Study. <i>Journal of Neuroscience</i> , 2012, 32, 1353-1359.	3.6	152
90	Increased Stress-Induced Dopamine Release in Psychosis. <i>Biological Psychiatry</i> , 2012, 71, 561-567.	1.3	222

#	ARTICLE	IF	CITATIONS
91	Dopamine response to psychosocial stress in humans and its relationship to individual differences in personality traits. <i>Journal of Psychiatric Research</i> , 2012, 46, 890-897.	3.1	26
92	Serotonin Transporter Occupancy and the Functional Neuroanatomic Effects of Citalopram in Geriatric Depression. <i>American Journal of Geriatric Psychiatry</i> , 2011, 19, 1016-1025.	1.2	27
93	Effects of antipsychotics on D3 receptors: A clinical PET study in first episode antipsychotic naive patients with schizophrenia using [ <sup>11</sup> C]-(+)-PHNO. <i>Schizophrenia Research</i> , 2011, 131, 63-68.	2.0	78
94	Analysis of Variance in Neuroreceptor Ligand Imaging Studies. <i>PLoS ONE</i> , 2011, 6, e23298.	2.5	3
95	Quantitation of Translocator Protein Binding in Human Brain with the Novel Radioligand [ <sup>18</sup> F]-FEPPA and Positron Emission Tomography. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2011, 31, 1807-1816.	4.3	98
96	Relationship of monoamine oxidase A binding to adaptive and maladaptive personality traits. <i>Psychological Medicine</i> , 2011, 41, 1051-1060.	4.5	43
97	Monoamine oxidase A inhibitor occupancy during treatment of major depressive episodes with moclobemide or St. John's wort: an [ <sup>11</sup> C]-harmine PET study. <i>Journal of Psychiatry and Neuroscience</i> , 2011, 36, 375-382.	2.4	49
98	Monoamine Oxidase A Binding in the Prefrontal and Anterior Cingulate Cortices During Acute Withdrawal From Heavy Cigarette Smoking. <i>Archives of General Psychiatry</i> , 2011, 68, 817.	12.3	67
99	Optimal transcranial magnetic stimulation coil placement for targeting the dorsolateral prefrontal cortex using novel magnetic resonance image-guided neuronavigation. <i>Human Brain Mapping</i> , 2010, 31, 1643-1652.	3.6	188
100	Extrasriatal dopaminergic dysfunction in tourette syndrome. <i>Annals of Neurology</i> , 2010, 67, 170-181.	5.3	92
101	Influence of a low dose of amphetamine on vesicular monoamine transporter binding: A PET (+)[ <sup>11</sup> C]DTBZ study in humans. <i>Synapse</i> , 2010, 64, 417-420.	1.2	19
102	Elevated Brain Monoamine Oxidase A Binding in the Early Postpartum Period. <i>Archives of General Psychiatry</i> , 2010, 67, 468.	12.3	177
103	Serotonin 2A Receptors and Visual Hallucinations in Parkinson Disease. <i>Archives of Neurology</i> , 2010, 67, 416-21.	4.5	220
104	Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[ <sup>11</sup> C]DASB and structural brain imaging study. <i>Brain</i> , 2010, 133, 1779-1797.	7.6	134
105	Parkinson's disease, impulse control disorder and the D3 dopamine receptor system: Preliminary PET imaging studies with [ <sup>11</sup> C](+)-PHNO comparison with [ <sup>11</sup> C]racloride. <i>NeuroImage</i> , 2010, 52, S84.	4.2	0
106	Quantification of translocator protein (18kDa) in the human brain with PET and a novel radioligand, [ <sup>18</sup> F]-FEPPA. <i>NeuroImage</i> , 2010, 52, S134.	4.2	0
107	Brain Monoamine Oxidase A Binding in Major Depressive Disorder. <i>Archives of General Psychiatry</i> , 2009, 66, 1304.	12.3	166
108	The Effect of Antipsychotics on the High-Affinity State of D2 and D3 Receptors. <i>Archives of General Psychiatry</i> , 2009, 66, 606.	12.3	97

#	ARTICLE	IF	CITATIONS
109	Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease. <i>Brain</i> , 2009, 132, 1366-1375.	7.6	93
110	Potential of Gamma Oscillatory Activity through Repetitive Transcranial Magnetic Stimulation of the Dorsolateral Prefrontal Cortex. <i>Neuropsychopharmacology</i> , 2009, 34, 2359-2367.	5.4	98
111	Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. <i>Brain</i> , 2009, 132, 1376-1385.	7.6	475
112	The relationship between subjective well-being and dopamine D2 receptors in patients treated with a dopamine partial agonist and full antagonist antipsychotics. <i>International Journal of Neuropsychopharmacology</i> , 2009, 12, 715.	2.1	52
113	The Dopamine D2 Receptors in High-Affinity State and D3 Receptors in Schizophrenia: A Clinical [11C]-(+)-PHNO PET Study. <i>Neuropsychopharmacology</i> , 2009, 34, 1078-1086.	5.4	109
114	Increased dopamine release in the right anterior cingulate cortex during the performance of a sorting task: A [11C]FLB 457 PET study. <i>NeuroImage</i> , 2009, 46, 516-521.	4.2	60
115	Elevated serotonin transporter binding in depressed patients with Parkinson's disease: A preliminary PET study with [ <sup>11</sup> C]DASB. <i>Movement Disorders</i> , 2008, 23, 1776-1780.	3.9	155
116	Brain region binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humans. <i>Human Brain Mapping</i> , 2008, 29, 400-410.	3.6	95
117	Evaluating the Relationship between Long Interval Cortical Inhibition, Working Memory and Gamma Band Activity in the Dorsolateral Prefrontal Cortex. <i>Clinical EEG and Neuroscience</i> , 2008, 39, 150-155.	1.7	44
118	First Human Evidence of d-Amphetamine Induced Displacement of a D2/3 Agonist Radioligand: A [11C]-(+)-PHNO Positron Emission Tomography Study. <i>Neuropsychopharmacology</i> , 2008, 33, 279-289.	5.4	109
119	Increased Vesicular Monoamine Transporter Binding during Early Abstinence In Human Methamphetamine Users: Is VMAT2 a Stable Dopamine Neuron Biomarker?. <i>Journal of Neuroscience</i> , 2008, 28, 9850-9856.	3.6	86
120	Adverse Subjective Experience With Antipsychotics and Its Relationship to Striatal and Extrastriatal D <sub>2</sub> Receptors: a PET Study in Schizophrenia. <i>American Journal of Psychiatry</i> , 2007, 164, 630-637.	7.2	141
121	A Positron Emission Tomography Study of 5-Hydroxytryptamine-1A Receptors in Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2007, 15, 888-898.	1.2	45
122	Positron Emission Tomography Quantification of [11C]-(+)-PHNO Binding in the Human Brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2007, 27, 857-871.	4.3	88
123	Brain serotonin transporter binding in non-depressed patients with Parkinson's disease. <i>European Journal of Neurology</i> , 2007, 14, 523-528.	3.3	182
124	Serotonin-1A receptors in frontotemporal dementia compared with controls. <i>Psychiatry Research - Neuroimaging</i> , 2007, 156, 247-250.	1.8	33
125	Serotonin transporter occupancy of high-dose selective serotonin reuptake inhibitors during major depressive disorder measured with [11C]DASB positron emission tomography. <i>Psychopharmacology</i> , 2007, 193, 539-545.	3.1	61
126	An automated method for the extraction of regional data from PET images. <i>Psychiatry Research - Neuroimaging</i> , 2006, 147, 79-89.	1.8	148